Condition: Recurrent Oligodendroglioma · Progressive Oligodendroglioma · Sponsor: University of Florida
This study will enroll 6 DLT evaluable subjects (up to 12 patients total) where we will evaluate feasibility and safety of adoptive cellular therapy combined with IDH1/2 inhibitors in patients with recurrent or progressive oligodendroglioma WHO grade 2 and WHO grade 3.
This description comes directly from the study's public registry record.
Phuong Deleyrolle, RN · 352-273-9000 · phuong.deleyrolle@neurosurgery.ufl.edu
Always discuss trial participation with your own doctor first.
| University of Florida Health Shands Hospital | Gainesville, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06254326